AR085200A1 - MEJORA EN LAS RESPUESTAS ESPECIFICAS A PATOGENOS DE LAS CELULAS DE MEMORIA Th17 - Google Patents
MEJORA EN LAS RESPUESTAS ESPECIFICAS A PATOGENOS DE LAS CELULAS DE MEMORIA Th17Info
- Publication number
- AR085200A1 AR085200A1 ARP110104073A ARP110104073A AR085200A1 AR 085200 A1 AR085200 A1 AR 085200A1 AR P110104073 A ARP110104073 A AR P110104073A AR P110104073 A ARP110104073 A AR P110104073A AR 085200 A1 AR085200 A1 AR 085200A1
- Authority
- AR
- Argentina
- Prior art keywords
- improvement
- cell responses
- pathogens
- memory cells
- improve
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones y métodos para mejorar las respuestas de células Th1/Th17 y disminuir las respuestas de células Th2. En diversas formas de realización se describe la activación de las células dendríticas humanas y la mejora de las respuestas de células T específicas del antígeno en células dendríticas humanas que expresan Dectina-1 que comprenden un anticuerpo anti-Dectina-1 específico, o un fragmento del mismo, fusionado con uno o más antígenos. También se pueden incluir ligandos TLR2 para mejorar la activación y para mejorar las respuestas de las células T. Además, también incluye métodos basados en las composiciones que se describen en la presente para el tratamiento de infecciones patógenas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40950710P | 2010-11-02 | 2010-11-02 | |
US13/282,112 US20120128710A1 (en) | 2010-11-02 | 2011-10-26 | Enhancement of Pathogen-Specific Memory Th17 Cell Responses |
Publications (1)
Publication Number | Publication Date |
---|---|
AR085200A1 true AR085200A1 (es) | 2013-09-18 |
Family
ID=46024782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104073A AR085200A1 (es) | 2010-11-02 | 2011-11-02 | MEJORA EN LAS RESPUESTAS ESPECIFICAS A PATOGENOS DE LAS CELULAS DE MEMORIA Th17 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20120128710A1 (es) |
EP (1) | EP2635305A4 (es) |
AR (1) | AR085200A1 (es) |
AU (1) | AU2011323695A1 (es) |
CA (1) | CA2816454A1 (es) |
TW (1) | TW201223544A (es) |
WO (1) | WO2012061203A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9045542B2 (en) | 2011-08-29 | 2015-06-02 | Baylor Research Institute | Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2) |
JP6566941B2 (ja) | 2013-06-28 | 2019-08-28 | ベイラー リサーチ インスティテュートBaylor Research Institute | 多発性硬化症のための樹状細胞asgpr標的化免疫治療薬 |
AU2015270845B2 (en) * | 2014-06-02 | 2019-09-12 | Baylor Research Institute | Methods and compositions for treating allergy and inflammatory diseases |
CN109207425A (zh) * | 2018-09-29 | 2019-01-15 | 中国医科大学附属口腔医院 | 牙龈卟啉单胞菌诱导巨噬细胞外泌体rna表达研究方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200502391A (en) * | 2003-05-08 | 2005-01-16 | Xcyte Therapies Inc | Generation and isolation of antigen-specific t cells |
JP5543785B2 (ja) * | 2007-02-02 | 2014-07-09 | ベイラー リサーチ インスティテュート | ヒト化ターゲティングモノクローナル抗体と複合体を形成する複数の可変抗原 |
CN101679949B (zh) * | 2007-02-23 | 2015-08-19 | 贝勒研究院 | 通过dectin-1激活人抗原呈递细胞的治疗性应用 |
JP5984388B2 (ja) * | 2008-07-16 | 2016-09-06 | ベイラー リサーチ インスティテュートBaylor Research Institute | 最大限のgag及びnefを樹状細胞に対して標的化することに基づくhivワクチン |
RU2012152828A (ru) * | 2010-05-07 | 2014-06-20 | Бейлор Рисёч Инститьют | Опосредованное иммунорецепторами дендритных клеток (dcir) перекрестное примирование cd8+ т клеток человека |
-
2011
- 2011-10-26 US US13/282,112 patent/US20120128710A1/en not_active Abandoned
- 2011-10-27 EP EP11838568.1A patent/EP2635305A4/en not_active Withdrawn
- 2011-10-27 AU AU2011323695A patent/AU2011323695A1/en not_active Abandoned
- 2011-10-27 CA CA2816454A patent/CA2816454A1/en not_active Abandoned
- 2011-10-27 WO PCT/US2011/058124 patent/WO2012061203A1/en active Application Filing
- 2011-11-02 TW TW100140009A patent/TW201223544A/zh unknown
- 2011-11-02 AR ARP110104073A patent/AR085200A1/es unknown
-
2014
- 2014-09-12 US US14/484,599 patent/US20150064205A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2635305A4 (en) | 2014-05-28 |
TW201223544A (en) | 2012-06-16 |
EP2635305A1 (en) | 2013-09-11 |
US20150064205A1 (en) | 2015-03-05 |
AU2011323695A1 (en) | 2013-05-23 |
WO2012061203A1 (en) | 2012-05-10 |
US20120128710A1 (en) | 2012-05-24 |
CA2816454A1 (en) | 2012-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123079T1 (el) | Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων | |
CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
CY1121217T1 (el) | Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων | |
UY33647A (es) | ?agentes de unión a cd33?. | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
EA201591761A1 (ru) | Композиции на основе наночастиц | |
PE20151893A1 (es) | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular | |
ECSP13013101A (es) | Moléculas que se unen a cd3 capaces de unirse a cd3 humano y no humano | |
EA201591454A1 (ru) | Связывающие внеклеточный матрикс синтетические пептидогликаны | |
BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
CR20120254A (es) | Células madre multipotenciales en el árbol de billary extrahepática y métodos de aislamiento del mismo | |
UY34317A (es) | Anticuerpo antireceptor de célula T (alfa)/ß | |
TWD168137S (zh) | 夾盤載具片 | |
ES2479542T1 (es) | Métodos y composiciones para su uso en terapias celulares | |
DK2928923T3 (da) | Antistoffer mod dendritisk celle-antigen 2 fra blod og anvendelser deraf | |
AR085409A1 (es) | Firmas microbianas como indicadores de exposicon a radiacion | |
EA201500080A1 (ru) | Способ in vitro диагностирования и мониторинга рака | |
MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
CY1120220T1 (el) | Μεθοδοι και κυτια για προσδιορισμο της καταστασης λοιμωξης απο φυματιωση | |
AR084263A1 (es) | Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) | |
CY1121795T1 (el) | Αντισωματα κατα toy cd52 | |
AR090668A1 (es) | Anticuerpo anti-adamts-5, derivados y usos del mismo | |
AR097293A1 (es) | Anticuerpo contra el receptor de tslp humana | |
AR085200A1 (es) | MEJORA EN LAS RESPUESTAS ESPECIFICAS A PATOGENOS DE LAS CELULAS DE MEMORIA Th17 | |
AR088220A1 (es) | Activacion de celulas dendriticas humanas por el receptor de dectina-1 o de tipo toll 2 (tlr2) en el control de la alergia y el asma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |